Clover (ASX:CLV) Shares Trail Record Profit As Cash Pressure Lingers

Clover punched out a record profit and the stock barely flinched. Shares closed at A$0.915 after a modest 7-day gain of about 7.6%, even as full year revenue reached A$97.4m and net profit after tax hit A$10.5m. The gap that really grabs attention is valuation. A trailing P/E of 14.5x and a discounted cash flow estimate of A$3.08 against a sub A$1 price set up a longer term question for investors weighing how much of this earnings story is already in the price.

Love Clover's A$10.5m profit and sub A$1 share price but unsure whether that discount is justified or a value trap in disguise? Line it up against other potential mispricings in our 6 high quality undervalued stocks

FY 2026 Earnings Summary

• Revenue (TTM vs TTM): A$97.41m for the 12 months to H2 FY 2026 vs. A$86.00m for the 12 months to H2 FY 2025 (up 13.3%)
• Net Income (Excl. Extra Items, TTM vs TTM): A$10.458m for the 12 months to H2 FY 2026 vs. A$7.015m for the 12 months to H2 FY 2025 (up 49.1%)
• Basic EPS (TTM vs TTM): A$0.0626 per share for the 12 months to H2 FY 2026 vs. A$0.0420 per share for the 12 months to H2 FY 2025 (up 49.1%)
• Net Profit Margin (TTM vs TTM): 10.7% for the 12 months to H2 FY 2026 vs. 8.2% for the 12 months to H2 FY 2025 (margin higher by 2.5 percentage points)

Prefer clean charts instead of another wall of spreadsheet rows and dense commentary? See Clover's full visual financial picture, including how its valuation compares with its recent profit performance, in our company report for Clover.

Clover’s growth story hits key execution markers

Bulls argue Clover can turn a niche omega ingredient base into a broader, higher margin nutrition platform. The latest year moves that claim from theory into something more concrete. Revenue reached A$97.4m, ahead of guidance, while net profit after tax rose to A$10.5m and gross margin stepped up to 35.5%. That margin lift aligns with management’s push into more specialised powders and diversified products, with 18+ offerings now making up about two thirds of H2 sales. Vertical integration is no longer just a PowerPoint slide. The Ecuador tuna oil facility now provides roughly 30% of inputs and the Melody Dairies joint venture is running near full capacity, both supporting cost control. ARA powder demand added roughly A$5m of extra sales, helped by completed qualifications with major infant formula customers, which backs the idea that product adoption cycles are actually converting into revenue and profit.

Bear case flags cash strain and execution friction

Sceptics worry Clover’s expansion story leans on long qualification cycles, heavy inventory and single point assets. The balance sheet gives that argument some bite. Net working capital climbed to A$49.8m, with inventory up about A$19.8m, and operating cashflow stayed tight despite higher earnings. That fits the concern that long supply chains and demand timing can trap cash and raise the risk of future write downs if orders slip. Capacity is another pressure point. Management openly links choline growth to securing more drying capability after unsuccessful attempts to acquire extra plant, so the choline program is still short of the scale milestone implied in the bullish narrative. Geographic mix also tells a more mixed story. ANZ and Europe grew, while Asia and the Americas eased, which keeps the question of distributor execution and regional diversification firmly on the table for investors tracking this thesis.

Compare Clover’s margin lift, product mix shift and capacity constraints with how the street is framing the story. See the consensus price target analysis for Clover

Stay Ahead With Clover And Simply Wall St

Clover’s record A$10.5m profit, sub A$1 share price and the gap to its A$3.08 DCF estimate make it a prime candidate to track closely, so register for free with Simply Wall St and add it to a Watchlist to watch how the share price moves against fair value and your own entry range. Once you decide to take or adjust a position, use the Portfolio Command Center to cut through noise and focus on key valuation shifts, earnings events and risk flags across all your holdings. For broader context on Clover and peers, join the Community to see how other investors are interpreting the same numbers and trade offs. Spot hidden catalysts and potential risks early, and use that edge to stay ahead of the market.

Seeking Alternatives Beyond Clover?

Fresh ideas move fast. Some tickers sit quiet, then momentum builds and prices start moving before many investors notice. Scan under-the-radar prospects while it matters to review potential opportunities early.

• Review resilient dividend payers that aim to keep income streams steady as markets swing by exploring our curated 3 dividend fortresses before yields change.
• Look for financially strong companies that prioritize balance sheet strength using the curated list of solid balance sheet and fundamentals stocks (12 results) while these under-the-radar candidates still trade before broader attention increases.
• Monitor early movers in nuclear infrastructure with the focused 19 nuclear energy infrastructure stocks while potential projects remain less widely followed, and evaluate them before momentum shifts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com